Glass pipettes with measurement marks in a chemical analysis laboratory of the Ferrer company.

R & D

PIPELINE

Every molecule in our pipeline is a tangible manifestation of our commitment to social justice

Our pipeline reflects how we turn science into solutions with a real impact on people's lives. It is the result of a clear commitment to advance in areas with unmet medical needs, where we can make a significant difference.

Each of the programmes that make it up responds to a deep understanding of the disease and its environment, and advances thanks to collaboration with multiple actors in the healthcare ecosystem. Because behind every project there is the same ambition: that each scientific advance reaches those who need it and contributes to improving their quality of life.

PIPELINE

The guidelines for the incorporation of new products into Ferrer's pipeline include the continuous search for new therapeutic options in indications for diseases with high mortality.

Once the opportunities in the selected indications have been identified, we evaluate and select the best opportunities according to very strict criteria that include the analysis of scientific soundness, clinical need, value positioning, technical and economic feasibility, also including a very exhaustive risk analysis.

Neurological diseases
PNF 253* – Huntington's disease (HD)

Phase 3
Neurological diseases
FNP 254* – Amyotrophic Lateral Sclerosis (ALS)

Phase 3
Neurological diseases
FNP 223 – Progressive Supranuclear Palsy (PSP)

Phase 2
Pulmonary vascular and interstitial lung diseases
Inhaled Treprostinil**$ – Pulmonary Hypertension – Interstitial Lung Disease (PH-ILD)

Market
Pulmonary vascular and interstitial lung diseases
Inhaled treprostinil** – Idiopathic Pulmonary Fibrosis (IPF)

Phase 3
Pulmonary vascular and interstitial lung diseases
Inhaled treprostinil** – Progressive Pulmonary Fibrosis (PPF)

Phase 3
Pulmonary vascular and interstitial lung diseases
FNP 321# – Medical Device for Pulmonary Arterial Hypertension (PAH)

Market
Pulmonary vascular and interstitial lung diseases
FNP 221 – Medical Device for Pulmonary Hypertension – Interstitial Lung Disease (HP-EPI)

Registration

Commitment and animal welfare

Together with the scientific community, we work with the long-term commitment to eliminate the use of animals in research and development programs. As such, we are committed to animal welfare in the following ways:

Documents on animal welfare policy next to a pen and Ferrer's corporate tape for good.

We outsource to third-party providers

Animal studies included in our research and development programmes, are required to demonstrate compliance with animal welfare, in accordance with Directive 2010/63/EU as amended by Regulation (EU) 2019/2010, and to comply with applicable local and national laws.
Legal and regulatory studies

We only sponsor animal studies if there is a specific legal or regulatory requirement to do so, in order to make a health benefit claim.